# BAY2328065 Single Dose Escalation, Safety and Tolerability, Pharmacokinetics, Relative Bioavailability, Food Effect

> **NCT03427788** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 72 (actual)

## Conditions studied

- Endometriosis

## Interventions

- **DRUG:** BAY2328065
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03427788
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-21
- **Primary completion:** 2018-10-29
- **Final completion:** 2019-02-11
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2024-02-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03427788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03427788, "BAY2328065 Single Dose Escalation, Safety and Tolerability, Pharmacokinetics, Relative Bioavailability, Food Effect". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03427788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*